(25 days)
Not Found
No
The device description details a chemical reaction and spectrophotometric measurement, with no mention of AI or ML. The performance studies focus on standard analytical chemistry metrics like correlation, precision, and linearity.
No.
Explanation: This assay is an in vitro diagnostic (IVD) device used for the quantitation of iron in human serum to assist in the diagnosis and treatment of diseases. It does not directly provide therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states that "Iron (non-heme) measurements are used in the diagnosis and treatment of diseases such as iron deficiency anemia, hemochromatosis... and chronic renal disease." This indicates the device provides information for diagnosis.
No
The device description clearly outlines a chemical assay that utilizes reagents and a physical analyzer (ALCYON 300/300i Analyzer) to measure iron concentration. This involves physical components and chemical reactions, not just software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the Iron assay is used for the "quantitation of iron in human serum" and that these measurements are used in the "diagnosis and treatment of diseases". This directly aligns with the definition of an IVD, which is used to examine specimens from the human body to provide information for the diagnosis, treatment, or prevention of disease.
- Device Description: The "Device Description" further clarifies that it is an "in vitro diagnostic assay for the quantitative determination of iron in human serum."
- Performance Studies: The "Summary of Performance Studies" describes comparative performance studies and precision studies, which are typical evaluations for IVD devices to demonstrate their accuracy and reliability.
- Predicate Device: The mention of a "Predicate Device(s)" with a K number (K864819) is a strong indicator that this device is being submitted for regulatory clearance as an IVD, as predicate devices are used for comparison in the regulatory process for new IVDs.
N/A
Intended Use / Indications for Use
The Iron assay is used for the quantitation of iron in human serum on the ALCYON 300/300i Analyzer. Iron (non-heme) measurements are used in the diagnosis and treatment of diseases such as iron deficiency anemia, hemochromatosis (a disease associated with widespread deposit in the tissues of two iron-containing pigments, hemosiderin and hemofuscin, and characterized by pigmentation of the skin), and chronic renal disease.
Product codes
JIY
Device Description
Iron is an in vitro diagnostic assay for the quantitative determination of iron in human serum. The Iron assay is a clinical chemistry assay which utilizes an acidic media to release ferric iron from the transferrin. The ferric iron is converted to the ferrous form by the action of hydroxylamine hydrochloride. The released ferrous iron reacts with FERENE® to produce a colored Iron-FERENE complex. The absorbance of the Iron-FERENE complex is measured at 600 nm and is proportional to the concentration of iron present in the sample. Thiourea and detergent are added to reduce copper interference and turbidity, respectively.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comparative performance studies were conducted using the ALCYON™ Analyzer. The Iron assay method comparison yielded acceptable correlation with the Raichem Serum Iron assay on the Roche Cobas Mira Plus Automated Chemistry System. The correlation coefficient = 0.9835, slope = 0.929, and Y-intercept = - 0.385 ug/dL. Precision studies were conducted using the Iron assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 111 is 2.7% and Level 2/Panel 112 is 5.5%. The Iron assay is linear up to 1,400 ug/dL. The limit of quantitation (sensitivity) of the Iron assay is 10 ug/dL. These data demonstrate that the performance of the Iron assay is substantially equivalent to the performance of the Raichem Serum Iron assay on the Roche Cobas Mira Plus Automated Chemistry System.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
The correlation coefficient = 0.9835, slope = 0.929, and Y-intercept = - 0.385 ug/dL. The total %CV for Level 1/Panel 111 is 2.7% and Level 2/Panel 112 is 5.5%. The Iron assay is linear up to 1,400 ug/dL. The limit of quantitation (sensitivity) of the Iron assay is 10 ug/dL.
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1410 Iron (non-heme) test system.
(a)
Identification. An iron (non-heme) test system is a device intended to measure iron (non-heme) in serum and plasma. Iron (non-heme) measurements are used in the diagnosis and treatment of diseases such as iron deficiency anemia, hemochromatosis (a disease associated with widespread deposit in the tissues of two iron-containing pigments, hemosiderin and hemofuscin, and characterized by pigmentation of the skin), and chronic renal disease.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
ADD CLIN CHEM
CONFILICATIA
2981241
1 1698 MAY
510(k) Summary
Fax (972) 753-3367
| Submitter's Name/Address | Abbott Laboratories |
|---|---|
| 1920 Hurd Drive | |
| Irving, Texas 75038 | |
| Contact Person | Mark Littlefield |
| Section Manager MS 1-8 | |
| Regulatory Affairs | |
| (972) 518-7861 |
| Date of Preparation of this Summary: | April 03, 1998 |
|---|---|
| Device Trade or Proprietary Name: | Iron |
| Device Common/Usual Name or Classification Name: | Iron |
| Classification Number/Class: | 75CFM/Class I |
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: _
Test Description:
Iron is an in vitro diagnostic assay for the quantitative determination of iron in human serum. The Iron assay is a clinical chemistry assay which utilizes an acidic media to release ferric iron from the transferrin. The ferric iron is converted to the ferrous form by the action of hydroxylamine hydrochloride. The released ferrous iron reacts with FERENE® to produce a colored Iron-FERENE complex. The absorbance of the Iron-FERENE complex is measured at 600 nm and is proportional to the concentration of iron present in the sample. Thiourea and detergent are added to reduce copper interference and turbidity, respectively.
Substantial Equivalence:
The Iron assay is substantially equivalent to the Raichem® Serum Iron assay (K864819) on the Roche® Cobas Mira® Plus Automated Chemistry System.
Iron 510(k) April 23, 1998 IronfE2a.lwp .
Section II Page 1
10
1
团 013
Both assay yield similar Performance Characteristics.
Similarities:
- Both assays are in vitro clinical chemistry methods. a
- Both assays can be used for the quantitative determination of iron. .
- Both assays yield similar clinical results. .
Differences:
- There is a difference between the assay range. .
Intended Use:
The Iron assay is used for the quantitation of iron in human serum ALCYON 300/300i Analyzer.
Performance Characteristics:
Comparative performance studies were conducted using the ALCYON™ Analyzer. The Iron assay method comparison yielded acceptable correlation with the Raichem Serum Iron assay on the Roche Cobas Mira Plus Automated Chemistry System. The correlation coefficient = 0.9835, slope = 0.929, and Y-intercept = - 0.385 ug/dL. Precision studies were conducted using the Iron assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 111 is 2.7% and Level 2/Panel 112 is 5.5%. The Iron assay is linear up to 1,400 ug/dL. The limit of quantitation (sensitivity) of the Iron assay is 10 ug/dL. These data demonstrate that the performance of the Iron assay is substantially equivalent to the performance of the Raichem Serum Iron assay on the Roche Cobas Mira Plus Automated Chemistry System.
Conclusion:
The Iron assay is substantially equivalent to the Raichem Serum Iron assay on the Roche Cobas Mira Plus Automated Chemistry System as demonstrated by results obtained in the studies.
Iron 510(k) April 23, 1998 IronfE2a Iwp
Section II Page 2
//
2
Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract image of an eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
1 1998 MAY
Mark Littlefield .Section Manager, Regulatory Affairs Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038
K981241 Re : Iron Requlatory Class: I Product Code: JIY Dated: April 3, 1998 Received: April 6, 1998
Dear Mr. Littlefield:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. ਮੈ substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as setforth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Litman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
CONFIDENTIAL
510(k) Number (if known):
Device Name: _________________________________________________________________________________________________________________________________________________________________ Iron
Indications For Use:
The Iron assay is used for the quantitation of iron in human serum on the ALCYON 300/300i Analyzer. Iron (non-heme) measurements are used in the diagnosis and treatment of diseases such as iron deficiency anemia, hemochromatosis (a disease associated with widespread deposit in the tissues of two iron-containing pigments, hemosiderin and hemofuscin, and characterized by pigmentation of the skin), and chronic renal disease.
(Division Sign-Off) Division of Clinical Laborato 510(k) Number .
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concyfrence of CDRH, Office of Device Evaluation (ODE) Prescription Use Over-The-Counter Use OR (Per 21 CFR 801.109)
(Optional Format 1-2-96)
g